In the first quarter of 2025, Regeneron faced headwinds, particularly with its Eylea franchise. The company reported a challenging period, with Eylea sales missing consensus expectations due to ...

Bayer A.G. ( OTCPK:BAYZF) ( OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the ...

This case involves an appeal from Regeneron Pharmaceuticals, Inc.’s (Regeneron) efforts to prevent defendants from marketing biosimilar versions ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Regeneron (NASDAQ: REGN) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its previous ...

An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea ...

German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of ...

BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data ...

A recent U.S. Court of Appeals decision has implications not only for companies in health care, but for any organization ...